We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that a late-stage study on its kidney cancer drug Inlyta (axitinib) failed to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS). Accordingly, an independent Data Monitoring Committee recommended the study be stopped at a planned interim analysis. Detailed data from the study will be presented at a future medical meeting.
The phase III ATLAS study was evaluating Inlyta versus placebo as an adjuvant therapy for patients with high risk of recurrent renal cell carcinoma (RCC), a type of kidney cancer, following surgical removal of one or both kidneys.
Shares of Pfizer have risen 0.2% so far this year, comparing favorably with a 2.3% decrease for the industry.
Inlyta is presently marketed for the second-line treatment of patients with advanced RCC. If the ATLAS study was successful, then Inlyta would be able to cater to an expanded patient population - kidney cancer patients who are in the earlier stage of this disease.
Inlyta generated sales of $339 million in 2017, a decline of 15% from 2016.
Meanwhile, Inlyta is being evaluated in two independent global phase III studies in combination with Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda and its own PD-L1 inhibitor Bavencio (avelumab), respectively – each compared with Sutent in first-line advanced RCC. These studies continue to be unmodified.
Bavencio is currently approved in metastatic MCC, a rare and aggressive skin cancer, in the United States, Europe and Japan and for the second-line treatment of locally advanced or metastatic urothelial carcinoma (accelerated approval) in the United States.
Pfizer has developed Bavencio in partnership with the German company, Merck KGaA (MKGAF - Free Report) . Meanwhile, avelumab is being developed for different types of cancer. The avelumab PD-L1 program has several studies ongoing, both as monotherapy and in combination with other portfolio assets.
Another top-ranked large-cap pharma stock is GlaxoSmithKline (GSK - Free Report) with the same Zacks Rank as Pfizer.
Shares of Glaxo have returned 17.5% this year so far. Estimates for 2018 and 2019 have increased by 3.9% and 4.8%, respectively, over the past 60 days.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenues and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
Pfizer Inc. (PFE - Free Report) announced that a late-stage study on its kidney cancer drug Inlyta (axitinib) failed to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS). Accordingly, an independent Data Monitoring Committee recommended the study be stopped at a planned interim analysis. Detailed data from the study will be presented at a future medical meeting.
The phase III ATLAS study was evaluating Inlyta versus placebo as an adjuvant therapy for patients with high risk of recurrent renal cell carcinoma (RCC), a type of kidney cancer, following surgical removal of one or both kidneys.
Shares of Pfizer have risen 0.2% so far this year, comparing favorably with a 2.3% decrease for the industry.
Inlyta is presently marketed for the second-line treatment of patients with advanced RCC. If the ATLAS study was successful, then Inlyta would be able to cater to an expanded patient population - kidney cancer patients who are in the earlier stage of this disease.
Inlyta generated sales of $339 million in 2017, a decline of 15% from 2016.
Meanwhile, Inlyta is being evaluated in two independent global phase III studies in combination with Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda and its own PD-L1 inhibitor Bavencio (avelumab), respectively – each compared with Sutent in first-line advanced RCC. These studies continue to be unmodified.
Bavencio is currently approved in metastatic MCC, a rare and aggressive skin cancer, in the United States, Europe and Japan and for the second-line treatment of locally advanced or metastatic urothelial carcinoma (accelerated approval) in the United States.
Pfizer has developed Bavencio in partnership with the German company, Merck KGaA (MKGAF - Free Report) . Meanwhile, avelumab is being developed for different types of cancer. The avelumab PD-L1 program has several studies ongoing, both as monotherapy and in combination with other portfolio assets.
Zacks Rank & Key Pick
Pfizer carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Another top-ranked large-cap pharma stock is GlaxoSmithKline (GSK - Free Report) with the same Zacks Rank as Pfizer.
Shares of Glaxo have returned 17.5% this year so far. Estimates for 2018 and 2019 have increased by 3.9% and 4.8%, respectively, over the past 60 days.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenues and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>